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SHORT COMMUNICATION
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ABSTRACT
Several neurodegenerative disorders including Alzheimer’s disease (AD) have been connected with deregu-
lation of casein kinase 1 (CK1) activity. Inhibition of CK1 therefore presents a potential therapeutic strategy
against such pathologies. Recently, novel class of CK1-specific inhibitors with N-(benzo[d]thiazol-2-yl)-2-phe-
nylacetamide structural scaffold has been discovered. 1-(benzo[d]thiazol-2-yl)-3-phenylureas, on the other
hand, are known inhibitors amyloid-beta binding alcohol dehydrogenase (ABAD), an enzyme also involved
in pathophysiology of AD. Based on their tight structural similarity, we decided to evaluate series of previ-
ously published benzothiazolylphenylureas, originally designed as ABAD inhibitors, for their inhibitory
activity towards CK1. Several compounds were found to be submicromolar CK1 inhibitors. Moreover, two
compounds were found to inhibit both, ABAD and CK1. Such dual-activity could be of advantage for AD
treatment, as it would simultaneously target two distinct pathological processes involved in disease’s pro-
gression. Based on PAMPA testing both compounds were suggested to permeate the blood-brain barrier,
which makes them, together with their unique dual activity, interesting lead compounds for further
development.
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Introduction
Enzyme casein kinase 1 (CK1), a member of a Ser/Thr specific pro-
tein kinase superfamily, is ubiquitously expressed in eukaryotic
organisms. At least seven CK1 isoforms (a, b, c1–3, d, and e)
and their various splice variants have been currently identified in
mammals1. Aberrant functional regulation of CK1, such as its over-
expression or excessive activation, is implicated in the pathogen-
esis of many diseases including several neurodegenerative
disorders, namely Alzheimer’s disease (AD), Parkinson’s disease
(PD), amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTLD)1.
In connection to AD, it was suggested that isoform CK1d
(together with GSK3b) be responsible for tau phosphorylation2.
However, in distribution and co-localization studies CK1d was
rather associated to granulovacuolar degeneration bodies whereas
CK1a was observed to co-localize with neurofibrillary lesions3.
Additionally, isoform CK1e was found to modulate, either directly
or indirectly, the activity of c-secretase and consequently the pro-
duction of Ab. Accordingly, inhibitors of CK1e were able to reduce
Ab production by c-secretase, moreover, without affecting Notch
cleavage4. In PD CK1 seems to participate in phosphorylation of
a-synuclein and parkin, both proteins significantly involved in PD
pathophysiology1. ALS and FTLD are another two neurodegenera-
tive diseases connected with aberrant CK1d activity, which is
responsible for abnormal phosphorylation of diseases associated
protein TDP-435.
Taken together, CK1 inhibition presents a promising thera-
peutic strategy for the treatment and prevention of neurodegener-
ative diseases mentioned above. So far, numerous CK1 inhibitors
have been described, which was comprehensively summarized by
Perez et al.1. Out of the currently known CK1-specific inhibitors,
compounds IC261 and D4476 were found with the highest select-
ivity and were characterized within in vitro and in vivo administra-
tion (Figure 1)1. However, there is a need for potent and isoform
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specific CK1 inhibitors with optimized pharmacological profile ena-
bling penetration through blood–brain barrier (BBB).
Recently, a series of N-(benzo[d]thiazol-2-yl)-2-phenylacetamides
have been described as novel class of selective CK1 inhibitors.
These compounds with IC50 for CK1d in nanomolar scale were pre-
dicted to cross BBB and showed protective effect on in vivo hTDP-
43 neurotoxicity Drosophila model, which makes them potential
pharmacological treatment of human TDP-43 proteinopathies such
as ALS as well as other neurodegenerative disorders connected
with abnormal CK1 activity6.
Above mentioned N-(benzo[d]thiazol-2-yl)-2-phenylacetamide
CK1 inhibitors are very similar in their structure to some 1-(ben-
zo[d]thiazol-2-yl)-3-phenylureas7, which were originally prepared
and tested as inhibitors of amyloid-beta binding alcohol dehydro-
genase (ABAD) for treatment of AD. They both (CK1 and ABAD
inhibitors) consist of benzothiazolyl and phenyl moiety connected
through the three-membered linker and in both cases, the benzo-
thiazolyl moiety is substituted in position 6 with small electron
withdrawing group (Figure 2)6,7. Therefore, the two structural
cores differ only by the “classical” bivalent isosteric replacement of
–CH2– by –NH– (Figure 2)
8.
Based upon this structural similarity we decided to evaluate the
inhibitory activity of the previously published benzothiazolylphe-
nylureas7 against CK1. Isoforms CK1d and CK1e were chosen for
the testing as they are mainly associated with neurodegenerative
disorders. Additionally, compounds inhibiting both, CK1d/e and
ABAD9, would be of further interest due to their simultaneous
action against two distinct pathological mechanisms involved in
AD and as such would present novel multi-target-directed ligands
(MTDLs) different from commonly developed MTDL
heterodimers10.
Experimental
Chemicals
Synthesis and identification of tested compounds was previously
published by Hroch et al.7
CK-1d and CK-1e assay protocol
The Kinase-Glo Kit was purchased from Promega (Promega
Biotech Iberica, SL) and was used to screen compounds for activity
against CK-1d and CK1e. Human recombinant Casein Kinase 1 delta
and epsilon was purchased from Millipore (Millipore Iberica S.A.U.).
Casein solution from bovine milk, 5%, was purchased from Sigma-
Aldrich (St. Louis, MO, USA). ATP and all other reagents were from
Sigma-Aldrich (St. Louis, MO, USA). Kinase-Glo assays were per-
formed in assay buffer using black 96-well plates. In a typical
assay, 10 mL of test compound (dissolved in DMSO at 1mM con-
centration and diluted in advance in assay buffer to the desired
concentration) 10mL (16 ng) of enzyme were added to each well
followed by 20mL of assay buffer containing 0.1% casein as sub-
strate and 4 mM ATP. The final DMSO concentration in the reaction
mixture did not exceed 1%. After 60min incubation at 30 C the
enzymatic reaction was stopped with 40mL of Kinase-Glo reagent.
Glow-type luminescence was recorded after 10min using a
FLUOstar Optima (BMG Labtechnologies GmbH, Offenburg,
Germany) multimode reader. The activity is proportional to the dif-
ference of the total and consumed ATP. The inhibitory activities
were calculated on the basis of maximal activities measured in the
absence of inhibitor. The IC50 was defined as the concentration of
each compound that reduces a 50% the enzymatic activity with
respect to that without inhibitors. Each value is the mean of two
independent experiments.
Calculation of physical chemical properties and CNS MPO score
Physical chemical properties of the tested compounds in the
unionized form were calculated in ACDLabs PhysChem Suite
14.011 – calculated logarithm of the n-octanol-water partition
coefficient for non-ionized species (ClogP); calculated n-octanol-
water distribution coefficient at pH¼ 7.4 (ClogD); molecular
weight (MW); topological polar surface area (TPSA); number of
hydrogen bond donors (HBD); logarithm of dissociation constant
for the most basic centre (pKa) and water solubility at
pH¼ 7.4 (ClogS7.4).
Parallel artificial membrane permeability assay (PAMPA)
Prediction of the BBB penetration was evaluated using a parallel
artificial membrane permeability assay (PAMPA) using the setup
according to Di et al.12. Ten commercial drugs, phosphate buffer
saline solution at pH 7.4 (PBS), Ethanol and dodecane were pur-
chased from Sigma, Acros organics, Merck, Aldrich and Fluka. The
porcine polar brain lipid (PBL) (catalogue no. 141101) was from
Avanti Polar Lipids. The donor plate was a 96-well filtrate plate
(MultiscreenVR IP Sterile Plate PDVF membrane, pore size is
0.45 mM, catalogue no. MAIPS4510) and the acceptor plate was an
indented 96-well plate (MultiscreenVR , catalogue no. MAMCS9610)
both from Millipore. Filter PDVF membrane units (diameter 30mm,
pore size 0.45 mm) from Symta were used to filtered the samples.
A 96-well plate UV reader (Thermo Scientific, Multiskan spectrum)
was used for the UV measurements. Test compounds [(3–5mg of
caffeine, enoxacine, hydrocortisone, desipramine, ofloxacine, pirox-
icam, and testosterone), (12mg of promazine) and 25mg of vera-
pamile and atenolol] were dissolved in EtOH (1000mL). About 100
mL of this compound stock solution was taken and 1400mL of
EtOH and 3500mL of PBS pH¼ 7.4 buffer were added to reach
30% of EtOH concentration in the experiment. These solutions
were filtered. The acceptor 96-well microplate was filled with
180 mL of PBS/EtOH (70/30). The donor 96-well plate was coated
with 4 mL of porcine brain lipid in dodecane (20mg mL1) and
after 5min, 180 mL of each compound solution was added. About
1–2mg of every compound to be determined their ability to pass
the brain barrier were dissolved in 1500 mL of EtOH and 3500 mL of
Figure 1. Structures of known CK1-selective inhibitors.
Figure 2. Structural similarity of CK1 and ABAD inhibitors.
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PBS pH¼ 7.4 buffer, filtered and then added to the donor 96-well
plate. Then the donor plate was carefully put on the acceptor
plate to form a “sandwich”, which was left undisturbed for 2 h and
30min at 25 C. During this time the compounds diffused from
the donor plate through the brain lipid membrane into the
acceptor plate. After incubation, the donor plate was removed. UV
plate reader determined the concentration of compounds and
commercial drugs in the acceptor and the donor wells. Every sam-
ple was analysed at three to five wavelengths, in three wells and
in two independent runs. Results are given as the mean [standard
deviation (SD)] and the average of the two runs is reported. 10
quality control compounds (previously mentioned) of known BBB
permeability were included in each experiment to validate the
analysis set.
Results and discussion
Compounds were screened against human recombinant enzyme
CK1d at a fixed concentration of 10mM. When the inhibition found
was more than 50%, IC50 value was determined and the most
potent compounds with an IC50 <1mM were further tested against
CK1e (Table 1).
All compounds showed at least some inhibitory activity
towards CK1d (Table 1). The most potent CK1d inhibitors
were found compounds K687, K689, K693, K699 and K703
with IC50 values lower than 0.5 mM. Regarding CK1e inhibition,
all compounds tested showed weaker activity compared to CK1d
inhibition. Best CK1e inhibitors K687 and K693 had IC50 values
around 2 mM. The selectivity of compounds towards CK1d inhib-
ition was indicated using the selectivity index (SI¼ IC50 CK1e/IC50
CK1d), which showed that the inhibitors are about 10 times more
active towards CK1d.
The best inhibitor found for both CK1d (IC50¼ 0.16mM) and
CK1e (IC50¼ 1.92mM) was compound K687 with chlorine substitu-
tion on benzothiazolyl moiety and hydroxyl group in position 3
of the phenyl ring. Generally, substitution in position 6 of benzo-
thiazolyl moiety with chlorine was superior to fluorine.
Substitution of the phenyl ring with either hydroxyl or carboxyl
group had positive effect on inhibitory activity possibly due to
their ability to act as HBD and therefore allowing additional
interaction with the enzyme. Only compounds K710 and K711
did not follow this trend being poor inhibitors. A possible
explanation for this discrepancy is that an intramolecular H-bond
is created between the hydroxyl and ester group resulting in
non-availability of the hydroxyl proton for hydrogen bonding
with the enzyme. As seen for compounds K684–K689 different
positioning of hydroxyl group on the phenyl ring had only lim-
ited influence on the activity. In contrast with the general SAR
stated here, the dimethoxy derivative K697 also showed good
inhibitory ability, although it does not possess a hydrogen bond
donor on its phenyl ring.
The best CK1d inhibitor K687 showed to be more potent in
comparison to standards IC261 (IC50¼ 1mM for both CK1d and
Table 1. Tested compounds and the results of their in vitro evaluation on CK1d/CK1e inhibition together with the previously published ABAD inhibition data7.
Compound R1 R2 IC50 CK1d (mM±SD) IC50 CK1e (mM±SD) SI
a
ABAD inhibition at 25 lM
(% of control ± SEM)
K684 F 4-OH 1.37 ± 0.23 NDb – 94.42 ± 1.13
K685 Cl 4-OH 0.59 ± 0.06 9.01 ± 0.37 15.3 91.93 ± 1.93
K686 F 3-OH 0.86 ± 0.10 4.02 ± 0.16 4.7 94.80 ± 0.97
K687 Cl 3-OH 0.16 ± 0.03 1.92 ± 0.38 12.0 93.58 ± 1.87
K688 F 2-OH 0.90 ± 0.14 7.33 ± 0.29 8.1 91.46 ± 1.51
K689 Cl 2-OH 0.48 ± 0.08 3.91 ± 0.40 8.1 77.06 ± 0.99
K690 F 3-Cl, 4-OH 0.84 ± 0.16 10.12 ± 0.74 12.0 39.76 ± 0.48
K691 Cl 3-Cl, 4-OH 0.73 ± 0.21 3.01 ± 0.33 4.1 38.61 ± 0.70
K692 F 3-COOH, 4-OH 0.91 ± 0.31 8.41 ± 0.71 9.2 101.30 ± 1.61
K693 Cl 3-COOH, 4-OH 0.40 ± 0.03 2.29 ± 0.12 5.7 100.54 ± 1.05
K694 F 4-OMe 7.38 ± 0.93 ND – 110.95 ± 1.84
K695 Cl 4-OMe 8.87 ± 0.73 ND – 104.55 ± 1.16
K696 F 3,4-OMe >10 (23%) ND – 103.59 ± 1.91
K697 Cl 3,4-OMe 0.69 ± 0.19 >10 (26%) >14.5 104.36 ± 1.45
K698 F 3-COOH, 4-OMe 3.37 ± 0.40 ND – 105.50 ± 1.48
K699 Cl 3-COOH, 4-OMe 0.46 ± 0.17 3.49 ± 0.09 7.6 107.22 ± 2.54
K700 F 4-OPh >10 (36%) ND – 108.75 ± 2.20
K701 Cl 4-OPh >10 (37%) ND – 107.42 ± 1.93
K702 F 4-COOH 2.99 ± 0.36 ND – 107.80 ± 1.75
K703 Cl 4-COOH 0.30 ± 0.04 3.69 ± 0.41 12.3 105.50 ± 1.68
K704 F 4-COOEt >10 (31%) ND – 110.28 ± 1.71
K705 Cl 4-COOEt >10 (45%) ND – 108.56 ± 2.21
K706 F 4-COOMe >10 (48%) ND – 114.67 ± 5.35
K707 Cl 4-COOMe 8.73 ± 0.71 ND – 99.31 ± 3.24
K708 F 4-NHCOMe >10 (39%) ND – 94.70 ± 3.27
K709 Cl 4-NHCOMe 1.32 ± 0.15 ND – 97.88 ± 3.40
K710 F 3-COOMe, 4-OH >10 (24%) ND – 97.23 ± 3.84
K711 Cl 3-COOMe, 4-OH 9.98 ± 0.96 ND – 95.62 ± 4.49
aSelectivity index¼ IC50CK1e/IC50CK1d.
bNot determined.
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CK1e) and D4476 (IC50¼ 0.2mM for CK1d), which are the most
characterized selective CK1 inhibitors for in vitro and in vivo appli-
cations1. Still, the best inhibitors developed by Salado et al.
showed even 10 times higher activity compared to K687, how-
ever, the increased activity was reserved only for compounds with
trifluoromethyl substitution in position 6 on benzothiazolyl moiety.
In direct comparison of 6-chloro and 6-flouro substituted com-
pounds, some benzothiazolylphenylureas showed slightly
increased activity compared to corresponding benzothiazolylphe-
nylacetamide6. This finding leads us to assumption, that replacing
of the chlorine substitution on the benzothiazole moiety of K687
with trifluoromethyl group could further improve the inhibi-
tory ability.
Most interestingly, compounds K690 and K691 showed good
inhibitory activity towards both CK1d (IC50¼ 0.84mM and 0.73mM)
and ABAD (39.8% and 38.6% inhibition at 10 mM7; IC50¼ 1.89mM
and 1.67 mM) and such dual-activity could be of advantage for tar-
geting AD. It is assumed that complex disorders, such as AD, could
be more effectively targeted by multipotent compounds (also
called multi-target directed ligands – MTDLs) able to intervene
simultaneously in the different pathological events underlying the
etiology of AD10,13.
One of the main obstacles for the treatment of the diseases
of the central nervous system (CNS) is the drug’s penetration
across the BBB at therapeutic concentrations. The BBB is a com-
plex interface between blood and the central nervous system
that strictly controls the exchanges between the blood and brain
compartments14. This barrier is composed by endothelial cells
with tight junctions that protect the brain from endogenous
materials which could damage the brain tissues15. The majority
of CNS drugs enter the brain by transcellular passive diffusion,
due to the tight junction structure and limited transport path-
ways. Thus, we have calculated the physical chemical properties11
of the tested compounds and used the CNS multiparametre opti-
mization (MPO) developed by Wager et al.16 to predict and com-
pare the likeliness of BBB-permeation. The MPO scoring function
is based on six fundamental physical chemical parameters com-
monly used by medicinal chemists – calculated partition coeffi-
cient (ClogP); calculated distribution coefficient at pH¼ 7.4
(ClogD); molecular weight (MW); TPSA; number of HBD; most
basic centre (pKa). All properties are weighted equally, with a
desirability score ranging from 0.0 to 1.0 for and therefore a total
CNS MPO desirability score ranges from 0.0 to 6.0. The MPO
score was found in optimal range (4) for about half of the
compounds (K684–K686, K688–K689, K694–K698, K702, K706,
K708–K709; Table 2), suggesting that these compounds are likely
to permeate through BBB. Looking at the separate physical
chemical parameters, the TPSA (TPSA¼ 40–90) and solubility
(ClogS7.4 (3)) were the most often violated predictors
(Table 2), which should be taken into account when designing
the follow-up series of CK1 resp. ABAD inhibitors. Although solu-
bility is not included in the MPO scoring function, it is crucial for
the prospective biological evaluation which cannot be properly
performed without reaching the desired concentrations of com-
pounds in aqueous solutions.
Detailed view at physical chemical properties of the most
promising compounds K690 and K691 (dual inhibitors of CK1 and
ABAD) revealed that both compounds do not fully meet the crite-
ria for BBB-penetration set by the CNS–MPO model16 showing
overall score 3.8 resp. 3.3 (optimal range ¼ 4–6). Both compounds
exceeded the optimal value of ClogP (3), ClogD (2), TPSA
(40–90) and HBD (0.5) with compound K690 having slightly bet-
ter results in the first two parameters. Still, both compounds fit
into the less strict criteria of “tolerable” values in the four above
mentioned parameters. The remaining two parameters MW (350)
and pKa (8) fully met the CNS-MPO criteria.
Table 2. Calculated physical chemical properties and MPO scoring for the urea compounds11,16.
PhysChemValues
Compound ClogP ClogD7.4 TPSA MW HBD pKa ClogS7.4 MPO
Optimal properties 1–5 0–3  (60–70) 400 3 4–10  (3) 4–6
K684 2.80 2.43 102.49 303.31 3 8.18 4.2 4.4
K685 3.40 2.92 102.49 319.77 3 8.00 4.4 4.1
K686 2.90 2.52 102.49 303.31 3 8.00 3.7 4.5
K687 3.60 3.11 102.49 319.77 3 7.82 4.2 3.9
K688 2.91 2.23 102.49 303.31 3 7.86 3.4 4.6
K689 3.50 2.68 102.49 319.77 3 7.68 4.2 4.2
K690 3.77 3.12 102.49 337.76 3 7.69 4.6 3.8
K691 4.33 3.54 102.49 354.21 3 7.51 4.9 3.3
K692 3.39 0.07 139.79 347.32 4 3.07 1.1 3.8
K693 3.90 0.36 139.79 363.78 4 3.07 1.6 3.5
K694 3.21 2.84 91.49 317.34 2 8.05 4.8 4.9
K695 3.89 3.42 91.49 333.79 2 7.87 5.0 4.3
K696 3.08 2.61 100.72 347.36 2 7.88 4.5 4.8
K697 3.71 3.12 100.72 363.82 2 7.71 4.6 4.2
K698 3.23 0.05 128.79 361.34 3 4.01 1.7 4.0
K699 3.63 0.26 128.79 377.80 3 4.01 1.9 3.7
K700 4.85 4.46 91.49 379.41 2 8.01 5.3 3.4
K701 5.44 4.94 91.49 395.86 2 7.83 5.8 3.2
K702 3.36 0.42 119.56 331.32 3 4.29 1.8 4.0
K703 3.93 0.89 119.56 347.78 3 4.29 2.4 3.7
K704 3.83 3.78 108.56 359.37 2 7.77 5.3 3.6
K705 4.50 4.42 108.56 375.83 2 7.59 5.9 3.0
K706 3.17 3.11 99.33 329.35 2 7.72 4.9 4.6
K707 3.80 3.72 99.33 345.80 2 7.54 5.7 3.9
K708 2.45 2.22 111.36 344.36 3 8.01 4.3 4.3
K709 3.05 2.74 111.36 360.82 3 7.84 4.9 4.1
K710 3.73 3.26 128.79 361.35 3 7.92 4.3 3.2
K711 4.29 3.70 128.79 377.80 3 7.74 4.7 2.5
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Parallel Artificial Membrane Permeability Assay (PAMPA) is tech-
nique developed to predict passive permeability through bio-
logical membranes. In order to further explore the capacity of
compounds K690 and K691 to penetrate into the brain, we used
the PAMPA–BBB method described by Di et al.12, which employed
a brain lipid porcine membrane. The in vitro permeability (Pe) of
commercial drugs through lipid membrane extract together with
compounds K690 and K691 were determined and described in
Table 3. An assay validation was made comparing the reported
permeability values of commercial drugs with the experimental
data obtained employing this methodology. A good correlation
between experimental-described values was obtained Pe
(exptl)¼ 0.79 (bibl) – 0.4064 (R2¼ 0.977) (Figure 3). From this
equation and following the pattern established in the literature for
BBB permeation prediction17 we could classify compounds as
CNSþwhen they present a permeability >2.75 106 cm s1.
Based on these results we can consider that compounds K690
and K691 are able to cross the BBB by passive permeation
(Table 3), although their calculated physical chemical properties
do not fully meet the criteria suggested by CNS-MPO model
(Table 2).
Conclusions
Based on structural similarity with known CK1 inhibitors, 28
compounds originally designed as ABAD inhibitors were eval-
uated for their inhibitory activity on CK1 and their potential to
cross the BBB was predicted using CNS-MPO model and eventu-
ally PAMPA. Several novel CK1 inhibitors with IC50 in high nano-
molar to low micromolar range were identified with compound
K687 being the best hit (IC50¼ 0.16mM/1.92 mM for CK1d resp.
CK1e). Moreover, compounds K690 and K691 were shown to
be low micromolar inhibitors of both, CK1 and ABAD, and
hence they present a potential novel class of dual-acting anti-
AD therapeutics. The results of PAMPA for K690 and K691 sug-
gests that the compounds should be able to penetrate into
the brain.
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